ARLINGTON, Va., Oct. 15 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, The Market Outlook for Research Products in FY2010. The 8.2 billion dollars appropriated to the NIH Scientific Research program by the American Recovery and Reinvestment Act is being earmarked for lab renovations, Challenge Grants, the Shared Instrumentation Program and research that spans multiple public and non-profit institutions, all of which will have an immediate and long-term impact on the life science tools industry. Comprised of responses from scientists with varying degrees of influence and purchasing authority in the lab, The Market Outlook for Research Products in FY2010 was designed to help provide insight as to how labs are going to allocate their budgets over the next fiscal year, how they are responding to the economic recession and where they believe their organizations are headed in FY2011.
The report is scheduled to release in mid-November, and is available at pre-release pricing until October 30, 2009.
The Market Outlook for Research Products in FY2010, includes detailed responses from nearly 800 scientists about their FY2010 budgets, planned expenditures and sources of funding. This study compares and contrasts FY2009 (actual) and FY2010 (projected) budgets in total, and by product category with a special focus on market segment and regional differences. European and U.S. scientists are asked about planned purchases of both consumables and instrumentation, and from what sources they expect to receive funding, with an emphasis on the ARRA. 61% of the survey respondents said that either they or someone in their lab applied for a recovery act grant.
In this report, scientists also indicate planned instrument and consumable purchases by vendor. The following suppliers were provided as some of the choices in the survey:
Abcam (LSE: ABC.L)
Abgene (Thermo Fisher Scientific (NYSE: TMO))
Affymetrix (Nasdaq: AFFX)
BD Biosciences (NYSE: BDX)
Bio-Rad (NYSE: BIO)
Beckman Coulter (NYSE: BEC)
BioSource (Life Technologies (Nasdaq: LIFE))
Calbiochem (EMD (NYSE: EMD))
Millipore (NYSE: MIL)
Dako (NYSE: CRM)
GE Healthcare (Amersham) (NYSE: GE)
Invitrogen (Life Technologies) (Nasdaq: LIFE)
Millipore (NYSE: MIL)
PerkinElmer (NYSE: PKI)
Qiagen (Nasdaq: QGEN)
Roche Applied Science
Sigma-Aldrich (Nasdaq: SIAL)
"This report will help life science suppliers identify practices scientists used to conserve expenses, and which promotions and incentives were the most enticing to labs," states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. Dr. Zemlo further notes that "Excerpts from this study can be used to inform reporting to management teams, boards of directors, analysts and investors."
To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/205/.
ABOUT BIOINFORMATICS, LLC
BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 43,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
For more information contact:
Mary Follin Manager, Marketing/Sales BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 703.778.3080 x13 (phone) email@example.com
SOURCE BioInformatics, LLC
|SOURCE BioInformatics, LLC|
Copyright©2009 PR Newswire.
All rights reserved